Sander Flaum, Principal of Flaum Navigators, believes that it’s absolutely essential that healthcare access is improved in the United States, but he has no confidence that anyone in Washington has the courage or clout to enact the substantial changes that need to be made.

Republican and Democratic U.S. senators called for a government analysis of foreign influence in the U.S. pharmaceutical supply chain, saying the coronavirus pandemic has exposed an over-reliance on China and other countries for the production of essential drugs.

A bill to encourage the manufacture of active pharmaceutical ingredients in America was introduced in the U.S. Senate by Senators Marsha Blackburn (R-TN) and Bob Menendez (R-NJ).

A bipartisan group of U.S. senators urged federal regulators to immediately remove all pod and cartridge-based e-cigarettes from the market until the products can be proven to be safe.

Days after the U.S. FDA revealed data manipulation was involved in the early studies of Novartis’ multi-million dollar gene therapy for SMA, U.S. Senate members demanded the regulatory agency take action against AveXis, the company that developed Zolgensma.

Three U.S. senators introduced a resolution in support of a moratorium and other limits on gene editing embryos.

The United States pays more per capita for prescription drugs than any other country in the world, which is a huge concern for patients and insurance providers.

U.S. Senator Elizabeth Warren urged former Food and Drug Administration Commissioner Scott Gottlieb to immediately step down from Pfizer Inc.’s board, three months after his departure from the health regulator.

U.S. Senators called drug pricing practices “morally repugnant” and told drug company executives they do not want to hear them blame others for the high prices, taking an aggressive stance at the start of a Senate hearing on the rising costs of prescription medicines.

U.S. Senator Bernie Sanders sent a letter to Catalyst Pharmaceuticals asking the company to justify the decision to charge $375,000 annually for a medication that for years has been available to patients for free.